Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
AFT Leaves X Over AI-Generated Images of Minors 
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Eli Lilly has officially entered the elite $1 trillion market-value club, becoming the first pharmaceutical company to reach this milestone. The company’s extraordinary rise is fueled largely by explosive global demand for weight-loss and diabetes treatments, a sector that has rapidly transformed into one of healthcare’s most lucrative markets.
Lilly’s stock has surged more than 35% this year thanks to the success of its blockbuster drug tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for obesity. In a remarkable shift, sales of these medicines have even surpassed Merck’s Keytruda, making tirzepatide the world’s best-selling drug. Mounjaro and Zepbound have also helped Lilly overtake longtime rival Novo Nordisk, which initially dominated the obesity-drug landscape. Novo’s Wegovy faced early supply shortages after its 2021 launch, giving Lilly crucial momentum. Stronger clinical results and faster manufacturing expansion further accelerated Lilly’s lead.
Shares briefly hit an all-time high near $1,051, and the stock now trades at a premium valuation—about 50 times expected earnings—reflecting investor confidence in long-term demand for GLP-1 treatments. Since Zepbound’s late-2023 debut, Lilly’s market performance has far outpaced the broader S&P 500, climbing more than 75%.
In the latest quarter, Lilly reported over $10 billion in combined obesity and diabetes drug revenue, representing more than half of its total $17.6 billion sales. Analysts say the company’s pipeline, pricing agreements with the U.S. government, and major domestic manufacturing investments position Lilly for continued dominance, even if near-term revenue faces pressure.
Wall Street projects the global weight-loss drug market could reach $150 billion by 2030, with Lilly poised to control a large share—especially as investors anticipate approval of its promising oral drug, orforglipron, next year.
Still, analysts caution that sustaining growth will require navigating price pressure, scaling production, and maintaining a strong pipeline. Even so, many now view Lilly as a potential alternative to tech-sector giants, especially as some AI stocks experience volatility.
